comparemela.com
Home
Live Updates
Biosimilar AVT04 Comparable to Ustekinumab in Treating Chronic Psoriasis : comparemela.com
Biosimilar AVT04 Comparable to Ustekinumab in Treating Chronic Psoriasis
The study met its primary endpoint of PASI improvement in the biosimilar and bio-originator cohorts.
Related Keywords
,
Baptist Stevenr Feldman ,
Stevenr Feldman ,
Wake Forest University School Of Medicine ,
Atrium Health ,
Department Of Dermatology ,
Expert Opinion ,
Wake Forest Baptist ,
Wake Forest University School ,
Global Assessment ,
comparemela.com © 2020. All Rights Reserved.